ALNY
Alnylam Pharmaceuticals Inc

4,380
Mkt Cap
$59.78B
Volume
1.82M
52W High
$495.55
52W Low
$205.87
PE Ratio
-184.86
ALNY Fundamentals
Price
$456.04
Prev Close
$449.56
Open
$449.00
50D MA
$460.37
Beta
0.92
Avg. Volume
1.14M
EPS (Annual)
-$2.18
P/B
238.36
Rev/Employee
$1.01M
Loading...
Loading...
News
all
press releases
ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales
Alnylam's Q3 earnings and revenues surge past forecasts, powered by booming Amvuttra sales and a key milestone payment from Roche.
Zacks·2d ago
News Placeholder
More News
News Placeholder
Compared to Estimates, Alnylam (ALNY) Q3 Earnings: A Look at Key Metrics
Although the revenue and EPS for Alnylam (ALNY) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks·3d ago
News Placeholder
Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates
Alnylam (ALNY) delivered earnings and revenue surprises of +73.65% and +22.25%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3d ago
News Placeholder
Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2025 and reviewed...
Business Wire·3d ago
News Placeholder
Zoetis Gears Up to Report Q3 Earnings: Here's What to Expect
ZTS is poised for another earnings beat as rising demand for companion animal products like Simparica Trio and Apoquel drives expected Q3 revenue growth.
Zacks·4d ago
News Placeholder
Amgen's Q3 Earnings in the Cards: Here's What to Expect
Amgen's Q3 results are on deck, with growth from newer drugs offset by biosimilar competition and pricing pressures.
Zacks·4d ago
News Placeholder
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
Strong Trikafta/Kaftrio demand, along with contributions from Alyftrek, Casgevy and Journavx, may have helped VRTX outperform in the third quarter.
Zacks·5d ago
News Placeholder
Exploring Analyst Estimates for Alnylam (ALNY) Q3 Earnings, Beyond Revenue and EPS
Evaluate the expected performance of Alnylam (ALNY) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Zacks·5d ago
News Placeholder
ANI Pharmaceuticals to Report Q3 Earnings: Is a Beat in the Cards?
ANIP's rising Cortrophin Gel sales and new rare disease products, along with generic and other segments, could power another earnings beat this quarter.
Zacks·6d ago
News Placeholder
Krystal Biotech, Inc. (KRYS) Reports Next Week: Wall Street Expects Earnings Growth
Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·6d ago

Latest ALNY News

View

Advertisement|Remove ads.

Advertisement|Remove ads.